The administration of the selective Cx43 hemichannel inhibitor TAT-Gap19 has been shown to decrease seizure activity in animal epilepsy models, indicating the involvement of Cx43 hemichannels in epilepsy [63]. This evidence concerns the gene GJA1 and epilepsy.